Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
Objective We report post hoc analyses of efficacy with first-line avelumab plus axitinib or sunitinib according to baseline neutrophil-to-eosinophil ratio (NER) in patients with advanced renal cell carcinoma (aRCC) from the JAVELIN Renal 101 phase 3 trial.Methods and analysis Progression-free surviv...
Saved in:
Main Authors: | Brian Rini, Mariangela Mariani, Alessandra di Pietro, Paul Nathan, Christian Kollmannsberger, Marc-Oliver Grimm, Martin H Voss, Bradley A McGregor, Mehmet A Bilen, Yoshihiko Tomita, Bo Huang, Robert Amezquita, Matthew Tucker, Yu-Wei Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-07-01
|
Series: | BMJ Oncology |
Online Access: | https://bmjoncology.bmj.com/content/3/1/e000181.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan
by: Norio Nonomura, et al.
Published: (2025-01-01) -
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
by: Ilya Tsimafeyeu, et al.
Published: (2024-12-01) -
Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age
by: Mototsugu Oya, et al.
Published: (2025-01-01) -
Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma
by: Jeannette C. Oosterwijk-Wakka, et al.
Published: (2025-02-01) -
Incidental Eosinophilic Chromophobe Renal Cell Carcinoma in Renal Allograft
by: Abdullah Alharbi, et al.
Published: (2017-01-01)